day 1 agenda
7th Edition of Innovations and State of the Art in ALZHEIMER'S & DEMENTIA on Sep 07-08, 2026 at Paris, France |
|
| Day -1(Sep 07, 2026) | |
| Tentative Program | |
| 09:00-09:30 | KeynoteTalk: Genetic Therapies for APOE4-Associated Alzheimer’s Diseases |
| Ronald Crystal, Weill Cornell Medicine, USA | |
| 09:30-10:00 | KeynoteTalk: GABA-A receptor modulating steroids enhance dementia, but antagonists inhibit inflammation and improve memory |
| Torbjörn Bäckström, Umeå University, Sweden | |
| 10:00-10:30 | KeynoteTalk: Glomerular (mesangial) amyloidogenesis in AL (light chain-associated) amyloidosis: Translational studies with implications for further treatment modalities. Similarities with amyloid formation in Alzheimer disease |
| Guillermo A. Herrera, University of South Alabama, USA | |
| Group Photo & Refreshment Break (10:30-10:50) | |
| Technical session-I | |
| 10:50-11:10 | Obtaining personalized predictions from a randomized controlled trial on Alzheimer’s disease |
| Dennis Shen, University of Southern California, USA | |
| 11:10-11:30 | The Traumatic brain injury and the risk of dementia |
| Wendy Lin, University of British Columbia, Canada | |
| 11:30-11:50 | Slot Available |
| 11:50-12:10 | Nonhuman Primate Models of Alzheimer’s Disease And Parkinson’sDisease Co-pathologies |
| Jeffrey H. Kordower, Arizona State University, USA | |
| 12:10-12:30 | Relationships among tau, amyloid, neuroinflammation, NMDA receptors and cognitive performance are strongly modulated by sex |
| Anat Biegon, University of Uppsala, Sweden | |
| 12:30-12:50 | Intermittent hypoxia training attenuates brain atrophy in elderly adultswith mild cognitive impairment |
| Xiangrong Shi, University of North Texas Health Science Centre, USA | |
| 12:50-13:10 | Slot Available |
| Lunch Break @ Restaurant (13:10-14:00) | |
| Technical session-II | |
| 14:00-14:20 | Arterial Tortuosity as a Marker of Cerebrovascular Aging and Dementia Risk |
| Yulin Ge, NYU Grossman School of Medicine, USA | |
| 14:20-14:40 | The Enigma of Brain Iron: From Brain Iron Overload to Functional Iron Deficiency in Neurodegenerative Diseases |
| Levi Sonia, University Vita-Salute San Raffaele , Italy | |
| 14:40-15:00 | Imaging oxidative stress in neurodegenerative disorders with Positron Emission Tomography with [18F]ROStrace |
| Robert H. Mach, University of Pennsylvania, USA | |
| 15:00-15:20 | Slot Available |
| 15:20-15:40 | Stepwise identification of prodromal dementia: testing a practical model for primary care |
| Boaz Levy, University of Massachusetts Boston, USA | |
| 15:40-16:00 | Cortical neuron dysfunction in AD brain at early-stage without beta-amyloid aggregation |
| Xiu-Ti Hu, Rush University Medical Center, USA | |
| 16:00-16:20 | Digital Twins in Clinical Trials for Alzheimer’s Disease |
| Irfan Chaudhuri, Harvard University, USA | |
| 16:20-16:40 | Slot Available |
| Refreshment Break(16:40-16:50) | |
| Note: This is a Tentative program, subjects and timings will changes. | |
| Day-1 Concludes | |
day 2 agenda
| Scientific Program | |
| 7th Edition of Innovations and State of the Art in ALZHEIMER'S & DEMENTIA |
|
| Sep 07 - 08, 2026 at Paris, France (Hybrid Event) | |
| Day -2 (September 08, 2026) | |
| Keynote Forum | 09:30-11:00 | |
| 11:00-11:20 | Group Photo & Refreshment Break | |
| Technical Session I | 11:20-13:00 | |
| 13:00-14:00 | Lunch Break | |
| Technical Session II | 14:00-16:00 | |
| 16:00-16:20 | Refreshment Break | |
| Technical Session III | 16:20-17:30 | |
| Panel Discussion & Closing Ceremony |
posters agenda
|
Day -1(Sep 07, 2026) |
||
|
Virtual Tentative Program followed by CET |
||
|
10:00-10:20 |
6-microRNA panel predicts amyloid-b status in cognitively normal older adults |
|
|
Joanna M. Williams, University of Otago, NewZealand |
||
|
10:20-10:40 |
Development of amyloid β (1-42) certified reference material NMIJ CRM 6210-a |
|
|
Kazumi Saikusa, National Metrology Institute of Japan (NMIJ), Japan |
||
|
10:40-11:00 |
Slot Available |
|
|
11:00-11:20 |
Huntingtin’s N17 region: Post-translational modifications as modulators of protein self-association and membrane interaction |
|
|
Mariana Gallo, University of Parma, Italy |
||
|
11:20-11:50 |
Keynote Talk: NAP, the investigational drug davunetide, from laboratory discovery to sex-specific cognitive protection in clinical trials |
|
|
Illana Gozes, Tel Aviv University, Israel |
||
|
11:50-12:10 |
Selective manipulation of aging as a novel treatment for neurodegenerative disorders |
|
|
Ehud Cohen, The Hebrew University School of Medicine, Israel |
||
|
12:10-12:30 |
Slot Available |
|
|
12:30-12:50 |
Early Linguistic Indicators and Language-Focused Therapies in Alzheimer’s Disease |
|
|
Erika Smeriglio, University of Messina, Italy |
||
|
12:50-13:10 |
Slot Available |
|
|
13:10-13:30 |
Correction of the APP London (V717I) mutation using |
|
|
Jacques P. Tremblay, Université Laval, Canada |
||
|
13:30-13:50 |
Methionine-sulfoxide based active immunization against Alzheimer’s disease |
|
|
Jackob Moskovitz, University of Kansas, USA |
||
|
13:50-14:20 |
Keynote Talk: Elovanoids: linking nutrition to neuroprotection |
|
|
Nicolas G. Bazan, Neuroscience Center of Excellence, USA |
||
|
14:20-14:40 |
Spiritual Fitness: The New Dimension In Alzheimer’s Disease Prevention |
|
|
Eve Adler, Alzheimer's Research and Prevention Foundation, USA |
||
|
14:40-15:00 |
The importance of social relationships in place in Alzheimer’s Disease |
|
|
George Rook, a person living with dementia and co-researcher on several projects, USA |
||
|
15:00-15:20 |
Slot Available |
|
|
15:20-15:40 |
Establishing two-tier cutoffs for ptau217/A42 ratio in plasma for detection of Alzheimers disease pathology |
|
|
Leslie M Shaw, University of Pennsylvania, USA |
||
|
15:40-16:00 |
Air pollution risk of Alzheimer in a mouse model of amyloidogenesis |
|
|
Caleb E Finch, University of Southern California, USA |
||
|
Day-1 Concludes |
||
|
Day -2(Sep 08, 2026) |
||
|
Virtual Tentative Program followed by CET |
||
|
10:00-10:20 |
Cultural Perspectives on Virtual delivery of Cognitive Stimulation Therapy for M?ori with Dementia (vCST-M?ori) |
|
|
Tai Kake, University of Auckland, NewZealand |
||
|
10:20-10:40 |
The therapeutic potential of medicinal cannabis for neurodegenerative diseases – a preclinical perspective |
|
|
Tim Karl, Western Sydney University, Australia |
||
|
10:40-11:00 |
Slot Available |
|
|
11:00-11:20 |
Revitalizing Mitochondria against Alzheimer’s disease: The Synergistic Effects of a Nutraceutical Combination with urolithin A |
|
|
Dona Pamoda W. Jayatunga, University of Sri Jayewardenepura, Sri Lanka |
||
| 11:20-11:50 | Keynote Talk: Restoring neuronal function by restoring the septin cytoskeleton |
| Gerard Griffioen, remynd, Belgium |
| 11:50-12:10 | Targeting the GSK3β/Nav1.6 protein–protein interaction offers a promising new therapeutic approach for early-stage Alzheimer’s disease |
| Fernanda Laezza, University of Texas Medical Branch, USA |
| 12:10-12:30 | Non-catalyzed covalent dimerization of amyloid b and implications for Alzheimer’s disease |
| Suren A. Tatulian, University of Central Florida, USA |
| 12:30-12:50 | Protein disulfide isomerase dissolves and detoxifies oligomeric assemblies of amyloid beta peptide |
| Ken Teter, University of Central Florida, USA |
| 12:50-13:10 | Molecular Mechanisms Underlying the Inverse Roles of Heme Function in Lung Cancer and Alzheimer’s Disease |
| Li Zhang, University of Texas at Dallas, USA |
| 13:10-13:30 | Slot Available |
| 13:30-13:50 | Alzheimer’s Is Dynamic – Our Language Has Not Kept Pace: Redefining Diagnosis Through Precision and Human-Centered Staging |
| Lauren P. Brown, The Alzheimer's Experience, USA |
| 13:50-14:20 | Keynote Talk: Systems Thinking |
| Michael Fossel, Michigan State University, USA |